research 213P Photobiomodulation therapy for the management of chemotherapy-induced alopecia: Preliminary results of a randomized, controlled trial
Photobiomodulation therapy may speed up hair regrowth after chemotherapy in the short term.
Search
for
Sort by
Research
180-210 / 1000+ results 
research Management of Advanced Prostate Cancer Undergoing Major Shift
New treatments are making advanced prostate cancer management more complex but also more hopeful.
research Combined Low Dose Oral Minoxidil and Immunomodulator Efficacy and Safety in Alopecia Areata: A Systematic Review
Combining low-dose oral minoxidil with immunomodulators shows promise for treating alopecia areata but needs more research.
research Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment
Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.
research Successful Treatment of Adalimumab-Induced Paradoxical Skin Reactions in Pustulotic Arthro-Osteitis With Guselkumab
Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.
research Severe Psoriasis Leading to Scarring Alopecia of the Scalp Responding to Biologic Therapy
Bimekizumab can improve scarring alopecia in severe psoriasis.
research The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.
research Mitoxantrone
Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.
research The Chinese State Food and Drug Administration has issued Sinovac Biotech a New Drug Certificate approving its split influenza vaccine
China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.
research Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
research 724 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin in adults with severe to very-severe alopecia areata
Rezpegaldesleukin shows promise for treating severe alopecia areata.
research Severe scarring alopecia associated with combinational use of ficlatuzumab and gefitinib: a clinical and immunohistochemistry study
Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
research Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B
research Etoposide sensitizes CT26 colorectal adenocarcinoma to radiation therapy in BALB/c mice
Etoposide makes radiation therapy more effective against tumors without major side effects.
research Baricitinib-Induced Remission of Alopecia Universalis in a Child with NFKB2-Associated Immune Dysregulation
research Simultaneous improvement of alopecia universalis and atopic dermatitis in a patient treated with a JAK inhibitor
A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
research 554 Repurposing a clinical antimalarial for the therapeutic induction of lethal ER stress targeting BRAF-kinase inhibitor-resistant malignant melanoma
Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.
research Old drug new indication: Tofacitinib for a new crop of hair?
Tofacitinib might be used to treat hair loss.
research B/N-doped carbon nano-onions as nanocarriers for targeted breast cancer therapy
Boron/nitrogen-doped carbon nano-onions improve targeted breast cancer treatment by enhancing drug delivery and reducing side effects.
research 43364 Long Term Real-World Patient-Reported Outcomes with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
research 320 An open label clinical trial of Abatacept (CTLA4-Ig) for alopecia areata
Abatacept may help some people with alopecia areata regrow hair.
research Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis
Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
research Alopecia areata after denosumab treatment for osteoporosis
Denosumab treatment for osteoporosis can cause hair loss.
research Secukinumab-Induced Alopecia Areata Successfully Treated with Tofacitinib in a Patient with Palmoplantar Pustulosis
Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.
research Anti‐keratin Monoclonal Antibody against Basal Cell Epithelioma Keratin: BKN‐1
BKN-1 antibody targets specific keratin in basal cell epithelioma and normal skin basal cells.
research [PRACTICAL EXPERIENCES WITH OVULATION INHIBITION].
Ovulation inhibitors effectively treat menstrual issues and improve fertility but can have side effects.
research SAT-240 Type B Insulin Resistance Resulting in Hyperthecosis in a Postmenopausal Woman
A woman's severe insulin resistance improved with treatment, but she still had high testosterone levels due to ovarian issues.
research The Comparative Safety of Epirubicin and Cyclophosphamide versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial
Epirubicin and cyclophosphamide cause more anemia and side effects than docetaxel and cyclophosphamide, but both are equally effective.
research POS0080 TOFACITINIB TREATMENT IN CHILDREN WITH RHEUMATIC DISEASES: SINGLE-CENTER EXPERIENCE
Tofacitinib is a promising treatment for children with rheumatic diseases.
research Delayed Onset of Alopecia Areata in a Patient on Ocrelizumab for Multiple Sclerosis: A Case Report
Ocrelizumab may cause delayed hair loss in some patients.